Molecular genetic testing for DCM involves testing a panel of genes, usually 30 to 50 through next-generation sequencing [34,42,43]. Mutations in genes encoding nuclear envelope proteins (such as lamin A and C), contractile apparatus (such as myosin heavy chain beta), membrane scaffolding (such as sarcoglycan), calcium handling proteins (such as phospholamban), and transcriptional and splicing machinery (such as ribonucleic acid-binding protein) have been identified as contributing factors [34,43]. Here, PLN is linked to familial dilated cardiomyopathy.